exhibit 10. 1 portions of the exhibit have been omitted from this exhibit 10. 1 since the information is both not material and is the type of information that the registrant customarily and actually treats as private and confidential. license agreement this license agreement ( the " agreement " ) is made at kolhapur on march 10, 2023 by and between nanoviricides, inc. a company incorporated under the laws of the state of nevada, and having its registered office at 1 controls drive, shelton, ct 06484 and its successors and assigns with offices ( hereinafter referred to as " nanoviricides " ) and m / s karveer meditech private limited ( cin - u24299pn2020ptc189325 ) a company incorporated under companies act, 2013 and having it registered office at plot no. 34, vijaya nagar, near shahu naka, ujalaiwadi, kolhapur, taluka - karveer, district - kolhapur, maharashtra, india 416004 and its successors and assigns ( hereinafter referred to as the " karveer " ) and all of whom are at times referred to as the " parties ". whereas, karveer is engaged in conducting research and development in the fields of pharmaceuticals and related activities, and has the necessary skill, experience, expertise, collaborations, and necessary facilities and infrastructure to provide the services contemplated under this agreement, and whereas, nanoviricides has researched and developed novel anti - viral drugs for the treatment of covid - 19, encompassing two clinical test drug candidates titled as nv - cov - 2 and nv - cov - 2 - r ( the " two clinical test drug candidates " ) for the treatment of covid - 19 patients, and whereas, karveer and nanoviricides have executed a master service agreement, dated september 15, 2021, wherein karveer has expressed an intent to license with an intent to sponsor these two clinical test drug candidates in india to perform the first - in - human phase i and phase ii human clinical trials in india for the purpose of evaluating the same for further development to potentially commercialize said drugs in india for the benefit of covid - 19 patients in the current pandemic, and whereas, karveer, as the drug sponsor in india, has received regulatory authorization from the new drug division